The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
35
68Ga-FAPI is a gallium-68 fibroblast activation protein inhibitor that will be injected into subjects during a PET (positron emission tomography) scan
Mayo Clinic in Rochester
Rochester, Minnesota, United States
RECRUITINGMyocardial 68Ga-FAPI (68Ga-Fibroblast Activation Protein Inhibitor) volume
Myocardial 68Ga-FAPI volume will be determined by a PET (positron emission tomography) scan and measured in cm3
Time frame: Baseline and 6 Months
Mean Standardized Uptake Value (SUVmean) and Max Standardized Uptake Value (SUVmax)
SUVmean and SUVmax will be determined by a PET (positron emission tomography) scan and measured as a dimensionless ratio
Time frame: Baseline and 6 Months
Area of 68Ga-FAPI (68Ga-Fibroblast Activation Protein Inhibitor) uptake
Area of 68Ga-FAPI will be determined by a PET (positron emission tomography) scan and measured as a % of polar map.
Time frame: Baseline and 6 Months
68Ga-FAPI target-to-background ratio
68Ga-FAPI target-to-background ratio will be determined by a PET (positron emission tomography) scan and measured as a dimensionless ratio.
Time frame: Baseline and 6 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.